Post hoc analysis of 1040 patients with AF and stable coronary disease: edoxaban alone vs edoxaban plus an antiplatelet had fewer total net adverse clinical events at 12 months (9.4 vs 19.8 per 100 person-years; IRR 0.47), mostly bleeding; ischaemic events and death similar.
Secondary analysisn = 1,040
Kim et al. Total Clinical Event Burden With Edoxaban Monotherapy Versus Dual Antithrombotic Therapy in Atrial Fibrillation and Stable Coronary Artery Disease: Insights From the EPIC-CAD Trial